Key result
Patients with stage IIA chronic heart failure had significantly higher beta-adrenoreactivity levels compared to those with stage I (61.8 vs 48.7 c.u., p=0.037).
Why the study?
The study was conducted to identify associations of beta-adrenoreactivity with the stage of chronic heart failure in patients with previous myocardial infarction.
Is beta-adrenoreactivity associated with the severity stage of chronic heart failure in patients with previous myocardial infarction?
Observational (n=50)
Is beta-adrenoreactivity associated with the severity stage of chronic heart failure in patients with previous myocardial infarction?
Absolute Event Rate: 61.8% vs 48.7%
p-value: p=0.037
Beta-adrenoreactivity may serve as a potential biomarker for assessing the severity of chronic heart failure in post-myocardial infarction patients.
Objective. To identify associations of beta-adrenoreactivity with stage of chronic heart failure (CHF) in patient with previousmyocardial infarction (MI).Material and Methods. A total of 50 patients with CHF underwent an analysis of adrenoreactivity based on the changes in red blood cellosmoresistance in the presence of adrenergic blocker to determine the activity of the sympathoadrenal system a year after MI.Results. Higher levels of beta-adrenoreactivity (β-ARM) were characteristic of patients with CHF of higher gradations: 61.8(47.5;74.8) с.u. in patients with stage IIA CHF versus 48.7 (39;65.2) с.u. in patients with stage I CHF, p=0.037.Conclusion. These results may suggest the diagnostic value of the indicator of adrenoreactivity and its possible use as a newbiomarker for assessing the severity of CHF in patients with previous myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Александренко et al. (2019) conducted an observational in Chronic heart failure with previous myocardial infarction (n=50). Stage IIA chronic heart failure vs. Stage I chronic heart failure was evaluated on Beta-adrenoreactivity (β-ARM) levels (p=0.037). Patients with stage IIA chronic heart failure had significantly higher beta-adrenoreactivity levels compared to those with stage I (61.8 vs 48.7 c.u., p=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: